Swedish biotech Gesynta Pharma has secured SEK 304 million ($29 million) in Series B funding to advance its novel non-hormonal endometriosis treatment. The round was led by Innovestor Life Science, with participation from existing and new investors including Hadean Ventures, Industrifonden, Linc, Foreground Capital, Catalyze Capital, Stephen Industries, and Amboy Street Ventures. The funding will support a Phase II clinical trial of…
Celmatix announced a new drug development program targeting endometriosis through a novel Jun-N-terminal kinase (JNK) inhibitor. The therapeutic candidate, developed using Baylor College of Medicine‘s DNA-Encoded Chemistry Technology platform, aims to address pain and inflammation associated with endometriosis. The program targets a significant medical need, as endometriosis affects over 10% of girls and women aged 15-45 worldwide. In the US, the condition…
New research from neurotech company Parasym has revealed that targeting the vagus nerve through neuromodulation can significantly reduce symptoms of endometriosis, a condition affecting 1 in 10 women in the UK. Parasym’s wearable device, Nurosym, has shown a 78% reduction in inflammation and a 50% increase in heart rate variability (HRV), which are key factors in managing endometriosis. Endometriosis occurs when tissue…
The National Institutes of Health (NIH) has announced a new initiative aimed at accelerating the development of non-invasive technologies for diagnosing endometriosis, a chronic condition that affects approximately 10% of reproductive-aged women worldwide. The RADx Tech ACT ENDO Challenge, co-led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Biomedical Imaging and…
Afynia Laboratories, a Canada-based startup led by former McMaster University researchers, has raised $1.5 million USD to advance the commercialization of their innovative endometriosis test, EndomiR. Co-founders Lauren Foster and Jocelyn Wessels aim to significantly improve the diagnostic process for endometriosis, a condition affecting millions of women globally. Afynia Laboratories, under the leadership of CEO Lauren Foster and Chief Scientific Officer Jocelyn…
Serac Healthcare, a clinical radiopharmaceutical company specializing in innovative molecular imaging technologies, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to 99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualization and diagnosis of superficial peritoneal endometriosis in women aged 16 and older. Fast Track designation is a process designed to facilitate the development and expedite…
TiumBio, a clinical-stage biopharmaceutical company based in South Korea, recently unveiled encouraging findings from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, aimed at alleviating moderate to severe endometriosis-associated pain. This announcement comes on the heels of a successful $12 million funding round, earmarked to advance the company’s clinical pipeline. The Phase 2a trial showcased promising…
Hera Biotech has shared interim findings from its ongoing clinical trial evaluating the MetriDx endometriosis diagnostic test. This trial, aimed at assessing the world’s first molecular, cell-based test for diagnosing and staging endometriosis without surgery, has reached the interim data analysis phase, shedding light on promising outcomes. Based on protocol data from the initial 38 participants enrolled in the 60-patient study, the…
